Abstract
Background Social distancing mandates have been effective at reducing the health impacts of COVID-19. The ensuing economic downturns and unemployment increases have led many nations to progressively relax mandates. As COVID-19 transmission and deaths rise in many low and middle-income countries (LMICs), with continuing widespread transmission elsewhere, policymakers are searching for options to reduce COVID-19 mortality without re-imposing strict social distancing mandates.
Methods Using a Bayesian meta-regression of 40 studies measuring the impact of mask use on respiratory viral infections, we estimated the reduction in transmission associated with the use of cloth or paper masks used in a general population setting. We used data from daily surveys conducted by Facebook, YouGov, and Premise, on the proportion of people reporting always wearing a mask outside their home for nearly all countries. We predicted deaths and infections until January 1st 2021 under a reference and universal mask use scenario using a deterministic transmission dynamics model with categories for susceptible, exposed, infected and recovered (SEIR). In the reference scenario, we assume continued easing of mandates but with action to re-impose mandates for a period of six weeks, at a level of eight daily deaths per million population. The universal mask scenario assumed scaling up of mask use to 95% over a one-week period.
Findings Use of simple masks can reduce transmission of COVID-19 by 40% (95% uncertainty interval [UI] 20% – 54%). Universal mask use would lead to a reduction of 815,600 deaths (95% UI 430,600 to 1,491,000 deaths) between August 26th 2020 and January 1st 2021, the difference between the predicted 3.00 million deaths (95% UI 2.20 to 4.52 million) in the reference and 2.18 million deaths (95% UI 1.71 to 3.14 million) in the universal mask scenario over this time period. Mask use was estimated at 59.0% of people globally on August 18th, ranging from 41.9% in North Africa and the Middle East to 79.2% in Latin America and the Caribbean. The effect of universal mask use is greatest in countries such as India (158,832 fewer deaths in universal mask scenario, 95% UI 75,152 to 282,838 deaths), the United States of America (93,495 fewer deaths; 95% UI 59,329 to 150,967 deaths), and Russia (68,531 fewer deaths; 95% UI 34,249 to 145,960 deaths).
Interpretation The rising toll of the COVID-19 pandemic can be substantially reduced by the universal adoption of masks. This low-cost policy, whether customary or mandated, has enormous health benefits and likely large economic benefits as well, by delaying the need for re-imposition of social distancing mandates.
Evidence before this study One meta-analysis of 21 studies reported a pooled reduction in the risk of respiratory virus infection of 47% (95% CI 36-79%) from a subset of eight studies reporting on mask use in non-health workers but it did not distinguish type of mask. Another meta-analysis reported on 26 studies of mask use in health workers and three studies in non-healthcare settings, reported a pooled effect of a 66% (55-74%) reduction in infections and a reduction by 44% (21-60%) in the three non-healthcare setting studies. Several survey series regularly measure self-reported mask use but results from these different sources have not previously been pooled to derive daily estimates of mask use over the course of the epidemic. Global models of the impact of scaled up mask use have to our knowledge not been published.
Added value of this study We combined the studies on mask use identified in the two meta-analyses and added one further study. In a Bayesian meta-regression approach, we derived the effect of simple cloth or paper masks used outside of a healthcare setting. In the meta-regression we make use of all the information provided by all of these studies, rather than subsetting to just those studies that provided the direct comparison of interest. Pooling estimates on the prevalence of self-reported mask use from three survey series provides up-to-date information on trends in mask use in almost all countries. We use extensive survey data covering nearly every country in the world to assess recent trends and current mask use. We then use an SEIR transmission dynamics model with good predictive validity to assess the potential of scaled up mask use to reduce global mortality from COVID-19.
Implications of all the available evidence Universal mask use can save many lives and avoid or, at least, delay the need for re-imposition of social mandates (such as stay-at-home orders, curfews, etc.), which would also contribute to ameliorating the negative effects of COVID-19 on the economy and unemployment. Until an affordable vaccine becomes universally available, mandating mask use is the most attractive policy option available to all countries, particularly if an expected increased transmission risk occurs in the Northern hemisphere’s fall and winter. Simple face coverings are cheap and effective; one of the few available interventions that is widely available to everyone. Countries with currently low mask use will need to determine the optimal balance between encouraging the use of masks through advocacy and information about their benefits, and governance of a compulsory use associated with penalties for non-compliance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Bill & Melinda Gates Foundation and Bloomberg Philanthropies. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the final report, or decision to publish. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We only use data collected by other entities.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available to researchers and where not freely available, information on how to access the data is provided.
